358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer
Britten, C., Wainberg, Z., Tabernero, J., Alsina Maqueda, M., Leong, S., Sessa, C., Millham, R., Gallo, J., Siu, L., Brana, I.Volume:
48
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(12)72156-1
Date:
November, 2012
File:
PDF, 55 KB
english, 2012